Trastuzumab
- TRADE NAME: Herceptin (Genentech)
- INDICATIONS: Metastatic breast cancer; stomach cancer
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Biologic, HER2/neu receptor antagonist (HER2 receptor antagonist), Monoclonal antibody, Tyrosine kinase inhibitor
- HALF-LIFE: 2–16 days (dose dependent)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Abciximab, Alefacept, Antineoplastics, Azacitidine, Betamethasone, Cabazitaxel, Denileukin, Docetaxel, Doxorubicin, Fingolimod, Gefitinib, Immunosuppressants, Leflunomide, Lenalidomide, Oxaliplatin, Paclitaxel, Pazopanib, Pemetrexed, Pralatrexate, Temsirolimus
PREGNANCY CATEGORY: D
CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of trastuzumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/16/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
